STOCKHOLM, Nov. 14, 2019 /PRNewswire/
-- "Following a record first half year, sales weakened
in the third quarter. However, the market situation and demand for
our products remain favorable and we have confidence in our
strategy"
Johan Löf, CEO of RaySearch. Comments on page
2.
THIRD QUARTER (JULY-SEPTEMBER
2019)
- Net sales SEK 144.3 M
(150.5)
- Result after tax SEK -7.5 M
(13.5) and earnings per share before/after dilution SEK -0.22 (0.39)
- Operating result SEK -6.3 M
(12.4)
- Cash flow SEK -13.5 M
(-17.0)
- Order intake SEK 196.8 M
(175.7)
NINE MONTHS (JANUARY-SEPTEMBER
2019)
- Net sales SEK 507.1 M
(407.8)
- Profit after tax SEK 31.5 M
(45.9) and earnings per share before/after dilution SEK 0.92 (1.34)
- Operating profit SEK 45.7 M
(52.8)
- Cash flow SEK -11.2 M
(-54.9)
- Order intake SEK 769.0 M
(510.3)
- Order backlog SEK 1,124.7 M
(740.4) at the end of the period
SIGNIFICANT EVENTS DURING THE THIRD QUARTER
- The RayStation® treatment planning system was chosen by several
leading cancer centers, including UC Davis Medical Center in the
US, Centre d'Oncologie Saint Vincent and Centre de Cancérologie les
Dentellières in France and Nagoya
City West Medical Center in Japan.
In addition, Emory Proton Therapy Center in the US expanded its
existing installation.
- RayCare 3A*, the latest version of RaySearch's oncology
information system, was released in July.
- RaySearch and Vision RT announced a strategic development
partnership.
- A ten-year rental lease was signed for a new head office in
Stockholm with commencement in the
third quarter of 2021.
SIGNIFICANT events AFTER THE END OF THE REPORTING
PERIOD
- RaySearch received new regulatory market clearance for
RayStation in China.
The information contained in this interim report was
submitted for publication on November 14,
2019 at at 7:45 a.m.
CET.
teleconference in connection with the interim
report
CEO Johan Löf and CFO
Peter Thysell will present
RaySearch's interim report for January-September 2019 at a teleconference in English on
Thursday, November 14, 2019 at
4:00 p.m. CET.
For login details to the teleconference, please register on:
http://emea.directeventreg.com/registration/3036698
FOR FURTHER INFORMATION, PLEASE CONTACT:
Johan Löf,
President and CEO
|
Tel: +46 8
510 530 00
|
E-mail:
johan.lof@raysearchlabs.com
|
Peter Thysell,
CFO
|
Tel: +46
70 661 05 59
|
E-mail:
peter.thysell@raysearchlabs.com
|
ABOUT RAYSEARCH
RaySearch Laboratories AB (publ) is a medical technology
company that develops innovative software solutions for improved
cancer treatment. The company develops and markets the RayStation
treatment planning system and RayCare oncology information system
to cancer centers all over the world and distributes the products
through licensing agreements with leading medical technology
companies. RaySearch's software is currently used by over 2,600
centers in more than 65 countries. The company was founded in 2000
as a spin-off from the Karolinska
Institute in Stockholm and
the share has been listed on Nasdaq Stockholm since 2003. More
information about RaySearch is available at
www.raysearchlabs.com.
This information was brought to you by Cision
http://news.cision.com
https://news.cision.com/raysearch-laboratories/r/interim-report-1-january---30-september-2019,c2961136
The following files are available for download:
https://mb.cision.com/Main/1102/2961136/1141012.pdf
|
The full report
(PDF)
|
View original
content:http://www.prnewswire.com/news-releases/interim-report-1-january---30-september-2019-300958154.html
SOURCE RaySearch Laboratories